New US Partner and a Tight Cash Position
Futura Medical (LSE:FUM), the developer of the Eroxon gel for erectile dysfunction, has replaced its United States commercial partner and is pursuing funding and wider strategic options as its cash runway shortens. In an update published on 1 September 2026 alongside half-year results, the company said Market Performance Group had become its US partner from 1 September, taking over from Haleon after a two-month transition. The half-year figures included a one-off settlement payment, and the board has indicated that new funding is needed in the near term to continue on its current plans.
What the Company Does
Futura Medical is a UK-based pharmaceutical company that develops sexual health products using its proprietary DermaSys transdermal delivery technology. Its lead product, Eroxon, is a topical gel for erectile dysfunction that is available without prescription in a number of markets. The company works through commercial partners, earning revenue from product supply, licensing and milestone payments rather than selling directly to consumers.
Latest Developments
Alongside the US change, Futura reported advancing discussions with partners in China, Korea, Taiwan and Turkey. Its follow-on product, Eroxon Intense, has received market clearance in the European Economic Area and the UK, and a home user test of 223 men aged 18 to 59 showed high efficacy, supporting a commercial launch. The company said it expects US Food and Drug Administration approval for Eroxon Intense in the fourth quarter.
Futura is also developing WSD4000, a gel for female sexual health. In a home user test, 80% of women reported an improved overall sexual experience, and early discussions with potential partners have begun in the US, Asia-Pacific, Europe and Latin America. Manufacturing of Eroxon is being consolidated under a single global strategic supplier.
Financial Picture
For the six months to 30 June 2026, revenue rose to £1.62m from £1.00m, although the figure included £1.4m from the settlement with Haleon. The operating loss narrowed to £1.2m from £6.72m, with the prior period including £4.05m of one-off costs. Cash was £1.06m at 31 July 2026, down from £1.24m at the end of June. The company said existing resources were expected to last only until about October without new funding, and the board is pursuing funding initiatives and wider strategic options. Futura does not pay a dividend.
Sector and Index Context
Futura is part of the FTSE AIM All Share Index, which includes many small healthcare and life sciences businesses that rely on partners to commercialise products. Consumer health companies operating in over-the-counter categories face high marketing costs and depend heavily on the commitment of their distribution partners. The departure of a major partner such as Haleon from the US market illustrates how quickly commercial plans can change.
Key Risks
The most immediate risk is funding. With guidance that cash would last only until around October, the company's ability to secure new capital or complete a strategic transaction is critical, and any share raise may be dilutive. Commercial risk remains significant, as Eroxon sales depend on partners' marketing efforts and consumer uptake. Regulatory timelines for Eroxon Intense in the US could slip, and supply chain consolidation carries execution risk.
What to Watch Next
Investors will watch closely for announcements on funding or strategic options, which given the company's guidance could come soon. Other milestones include an FDA decision on Eroxon Intense, early sales under Market Performance Group, the signing of agreements in Asia and Turkey and progress in partnering WSD4000.






Please wait processing your request...